Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy

References

• Bielekova B, Komori M, Xu Q, et al. (2012). Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One, 7, e48370. doi: 10.1371/journal.pone.0048370
   PubMed Web of Science ®Google Scholar
• Comar M, Zanotta N, Croci E, et al. (2012). Association between the JC polyomavirus infection and male infertility. PLoS One, 7, e42880. doi: 10.1371/journal.pone.0042880
   PubMed Web of Science ®Google Scholar
• Corcione A, Casazza S, Ferretti E, et al. (2004). Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A, 101, 11064–11069. doi: 10.1073/pnas.0402455101
   PubMed Web of Science ®Google Scholar
• De Oliveira DM, De Oliveira EM, Ferrari Mde F, et al. (2015). Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Inflammopharmacology, 23, 343–354. doi: 10.1007/s10787-015-0252-1
   PubMed Web of Science ®Google Scholar
• Falcone M, Scalise A, Minisci C, et al. (2006). Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Neurol Sci, 27, 58–62. doi: 10.1007/s10072-006-0565-3
   PubMed Web of Science ®Google Scholar
• Franciotta D, Zardini E, Ravaglia S, et al. (2006). Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. J Neurol Sci, 247, 202–207. doi: 10.1016/j.jns.2006.05.049
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. (2006). Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med, 354, 942–955. doi: 10.1056/NEJMra052130
   PubMed Web of Science ®Google Scholar
• Giunti D, Borsellino G, Benelli R, et al. (2003). Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol, 73, 584–590.
   PubMed Web of Science ®Google Scholar
• Guo W, Wang C, Wang X, et al. (2015). A novel human truncated IL12rbeta1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation. Oncotarget, 6, 28539–28555. doi: 10.18632/oncotarget.5164
   PubMed Web of Science ®Google Scholar
• Hanewinckel R, Ikram MA, Van Doorn PA. (2016). Peripheral neuropathies. Handb Clin Neurol, 138, 263–282. doi: 10.1016/B978-0-12-802973-2.00015-X
   PubMedGoogle Scholar
• Kingwell E, Marriott JJ, Jette N, et al. (2013). Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol, 13, 128. doi: 10.1186/1471-2377-13-128
   PubMed Web of Science ®Google Scholar
• Koller H, Kieseier BC, Jander S, Hartung HP. (2005). Chronic inflammatory demyelinating polyneuropathy. N Engl J Med, 352, 1343–1356. doi: 10.1056/NEJMra041347
   PubMed Web of Science ®Google Scholar
• Kothur K, Wienholt L, Brilot F, Dale RC. (2016). CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. Cytokine, 77, 227–237. doi: 10.1016/j.cyto.2015.10.001
   PubMed Web of Science ®Google Scholar
• Kwok S, Higuchi R. (1989). Avoiding false positives with PCR. Nature, 339, 237–238. doi: 10.1038/339237a0
   PubMed Web of Science ®Google Scholar
• Little J, Barakat-Haddad C, Martino R, et al. (2016). Genetic variation associated with the occurrence and progression of neurological disorders. Neurotoxicology. doi: 10.1016/j.neuro.2016.09.018
   Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. (2014). Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, 83, 278–286. doi: 10.1212/WNL.0000000000000560
   PubMed Web of Science ®Google Scholar
• Mathey EK, Park SB, Hughes RA, et al. (2015). Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry, 86, 973–985. doi: 10.1136/jnnp-2014-309697
   PubMed Web of Science ®Google Scholar
• Maxeiner HG, Marion Schneider E, Kurfiss ST, et al. (2014). Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine, 69, 62–67. doi: 10.1016/j.cyto.2014.05.008
   PubMed Web of Science ®Google Scholar
• Melzer N, Meuth SG. (2014). Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol, 175, 359–372. doi: 10.1111/cei.12195
   PubMed Web of Science ®Google Scholar
• Mendell JR, Kolkin S, Kissel JT, et al. (1987). Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology, 37, 1291–1294.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Gallia F. (2015). Update on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol, 28, 480–485. doi: 10.1097/WCO.0000000000000232
   PubMed Web of Science ®Google Scholar
• Orbach R, Gurevich M, Achiron A. (2014). Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome. Mult Scler, 20, 35–42. doi: 10.1177/1352458513491166
   PubMed Web of Science ®Google Scholar
• Ormerod IE, Waddy HM, Kermode AG, et al. (1990). Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatry, 53, 789–793.
   PubMed Web of Science ®Google Scholar
• Sainaghi PP, Collimedaglia L, Alciato F, et al. (2010). The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barre syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine, 51, 138–143. doi: 10.1016/j.cyto.2010.05.005
   PubMed Web of Science ®Google Scholar
• Sartori A, Fantini J, Manganotti P. (2017). How far away from having an effective treatment option for progressive multiple sclerosis are we? Expert Opin Pharmacother, 1–3. doi: 10.1080/14656566.2017.1326909
   Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, et al. (2008). Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol, 7, 796–804. doi: 10.1016/S1474-4422(08)70173-X
   PubMed Web of Science ®Google Scholar
• Shajarian M, Alsahebfosoul F, Etemadifar M, et al. (2015). IL-23 plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects. Immunol Invest, 44, 36–44. doi: 10.3109/08820139.2014.930477
   PubMed Web of Science ®Google Scholar
• Stein A, Panjwani A, Sison C, et al. (2013). Pilot study: elevated circulating levels of the proinflammatory cytokine macrophage migration inhibitory factor in patients with chronic spinal cord injury. Arch Phys Med Rehabil, 94, 1498–1507. doi: 10.1016/j.apmr.2013.04.004
   PubMed Web of Science ®Google Scholar
• Van Den Bergh PY, Hadden RD, Bouche P, et al., and Societies European Federation of Neurological, and Society Peripheral Nerve. (2010). European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society – first revision. Eur J Neurol, 17, 356–363. doi: 10.1111/j.1468-1331.2009.02930.x
   PubMed Web of Science ®Google Scholar
• Vidal-Jordana A, Montalban X. (2017). Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am, 27, 195–204. doi: 10.1016/j.nic.2016.12.001
   PubMed Web of Science ®Google Scholar
• Zanin V, Delbue S, Marcuzzi A, et al. (2012). Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders. J Neurovirol, 18, 416–422. doi: 10.1007/s13365-012-0109-y
   PubMed Web of Science ®Google Scholar